Abstract
This chapter questions the prevailing “implicit” assumption that molecular mechanisms and the biological phenotype of dominantly inherited early-onset alzheimer’s disease (EOAD) could serve as a linear model to study the pathogenesis of sporadic late-onset alzheimer’s disease (LOAD). Now there is growing evidence to suggest that such reductionism may not be warranted; these suppositions are not adequate to explain the molecular complexities of LOAD. For example, the failure of some recent amyloid-centric clinical trials, which were largely based on the extrapolations from EOAD biological phenotypes to the molecular mechanisms in the pathogenesis of LOAD, might be due to such false assumptions. The distinct difference in the biology of LOAD and EOAD is underscored by the presence of EOAD cases without evidence of familial clustering or Mendelian transmission and, conversely, the discovery and frequent reports of such clustering and transmission patterns in LOAD cases. The primary thesis of this chapter is that a radically different way of thinking is required for comprehensive explanations regarding the distinct complexities in the molecular pathogenesis of inherited and sporadic forms of Alzheimer’s disease (AD). We propose using longitudinal analytical methods and the paradigm of systems biology (using transcriptomics, proteomics, metabolomics, and lipidomics) to provide us a more comprehensive insight into the lifelong origin and progression of different molecular mechanisms and neurodegeneration. Such studies should aim to clarify the role of specific pathophysiological and signaling pathways such as neuroinflammation, altered lipid metabolism, apoptosis, oxidative stress, tau hyperphosphorylation, protein misfolding, tangle formation, and amyloidogenic cascade leading to overproduction and reduced clearance of aggregating amyloid-beta (Aβ) species. A more complete understanding of the distinct difference in molecular mechanisms, signaling pathways, as well as comparability of the various forms of AD is of paramount importance. The development of knowledge and technologies for early detection and characterization of the disease across all stages will improve the predictions regarding the course of the disease, prognosis, and response to treatment. No doubt such advances will have a significant impact on the clinical management of both EOAD and LOAD patients. The approach propped here, combining longitudinal studies with the systems biology paradigm, will create a more effective and comprehensive framework for development of prevention therapies in AD.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Blennow K, De Leon MJ, Zetterberg H (2006) Alzheimer’s disease. Lancet 368:387–403
Bertram L, Lill CM, Tanzi RE (2010) The genetics of Alzheimer disease: back to the future. Neuron 68:270–281
Bertram L, Tanzi RE (2012) The genetics of Alzheimer’s disease. Prog Mol Biol Transl Sci 107:79–100
Van Deerlin VM, Wood EM, Moore P et al (2007) Clinical, genetic, and pathologic characteristics of patients with frontotemporal dementia and progranulin mutations. Arch Neurol 64:1148–1153
Huey ED, Grafman J, Wassermann EM et al (2006) Characteristics of frontotemporal dementia patients with a Progranulin mutation. Ann Neurol 60:374–380
Perry DC, Lehmann M, Yokoyama JS et al (2013) Progranulin mutations as risk factors for Alzheimer disease. JAMA Neurol 70:774–778
Jin SC, Pastor P, Cooper B et al (2012) Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer’s disease Ibero-American cohort. Alzheimers Res Ther 4:34
Kelley BJ, Haidar W, Boeve BF et al (2010) Alzheimer disease-like phenotype associated with the c.154delA mutation in progranulin. Arch Neurol 67:171–177
Finch N, Baker M, Crook R et al (2009) Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 132:583–591
Brouwers N, Nuytemans K, van der Zee J et al (2007) Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol 64:1436–1446
Strittmatter WJ, Saunders AM, Schmechel D et al (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90:1977–1981
Bertram L, McQueen MB, Mullin K et al (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39:17–23
Harold D, Abraham R, Hollingworth P et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet 41:1088–1093
Lambert JC, Heath S, Even G et al (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet 41:1094–1099
Seshadri S, Fitzpatrick AL, Ikram MA et al (2010) Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303:1832–1840
Hollingworth P, Harold D, Sims R et al (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 43:429–435
Naj AC, Jun G, Beecham GW et al (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet 43:436–441
Zetzsche T, Rujescu D, Hardy J et al (2010) Advances and perspectives from genetic research: development of biological markers in Alzheimer’s disease. Expert Rev Mol Diagn 10:667–690
Jones L, Holmans PA, Hamshere ML et al (2010) Genetic evidence implicates the immune system and cholesterol metabolism in the etiology of Alzheimer’s disease. PLoS One 5:e13950
Lambert JC, Ibrahim-Verbaas CA, Harold D et al (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 45:1452–1458
Jonsson T, Stefansson H, Steinberg S et al (2013) Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med 368:107–116
Guerreiro R, Wojtas A, Bras J et al (2013) TREM2 variants in Alzheimer’s disease. N Engl J Med 368:117–127
Neumann H, Daly MJ (2013) Variant TREM2 as risk factor for Alzheimer’s disease. N Engl J Med 368:182–184
Chinn S (1989) Longitudinal studies: design and analysis. Rev Epidemiol Sante Publique 37:431–441
Gibbons RD (2008) Design and analysis of longitudinal studies. Psychiatr Ann 38:758–761
Liu C, Cripe TP, Kim MO (2010) Statistical issues in longitudinal data analysis for treatment efficacy studies in the biomedical sciences. Mol Ther 18:1724–1730
Hampel H, Lista S (2012) Alzheimer disease: from inherited to sporadic AD-crossing the biomarker bridge. Nat Rev Neurol 8:598–600
Hampel H, Lista S, Khachaturian ZS (2012) Development of biomarkers to chart all Alzheimer’s disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement 8:312–336
Hampel H, Lista S (2013) Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. J Nutr Health Aging 17:54–63
Rosén C, Hansson O, Blennow K et al (2013) Fluid biomarkers in Alzheimer’s disease - current concepts. Mol Neurodegener 8:20
Carrillo MC, Blennow K, Soares H et al (2013) Global standardization measurement of cerebral spinal fluid for Alzheimer’s disease: an update from the Alzheimer’s Association Global Biomarkers Consortium. Alzheimers Dement 9:137–140
Villemagne VL, Burnham S, Bourgeat P et al (2013) Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 12:357–367
Bateman RJ, Xiong C, Benzinger TL et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367:795–804
Noorbakhsh F, Overall CM, Power C (2009) Deciphering complex mechanisms in neurodegenerative diseases: the advent of systems biology. Trends Neurosci 32:88–100
Tyers M, Mann M (2003) From genomics to proteomics. Nature 422:193–197
Dong Z, Chen Y (2013) Transcriptomics: advances and approaches. Sci China Life Sci 56:960–967
Wang Z, Gerstein M, Snyder M (2009) RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10:57–63
Liang WS, Dunckley T, Beach TG et al (2008) Altered neuronal gene expression in brain regions differentially affected by Alzheimer’s disease: a reference data set. Physiol Genomics 33:240–256
Tan MG, Chua WT, Esiri MM et al (2010) Genome wide profiling of altered gene expression in the neocortex of Alzheimer’s disease. J Neurosci Res 88:1157–1169
Maes OC, Xu S, Yu B et al (2007) Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol Aging 28:1795–1809
Colangelo V, Schurr J, Ball MJ et al (2002) Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and upregulation of apoptotic and pro-inflammatory signaling. J Neurosci Res 70:462–473
Blalock EM, Geddes JW, Chen KC et al (2004) Incipient Alzheimer’s disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A 101:2173–2178
Yao PJ, Zhu M, Pyun EI et al (2003) Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer’s disease. Neurobiol Dis 12:97–109
Fehlbaum-Beurdeley P, Jarrige-Le Prado AC, Pallares D et al (2010) Toward an Alzheimer’s disease diagnosis via high-resolution blood gene expression. Alzheimers Dement 6:25–38
Chen KD, Chang PT, Ping YH et al (2011) Gene expression profiling of peripheral blood leukocytes identifies and validates ABCB1 as a novel biomarker for Alzheimer’s disease. Neurobiol Dis 43:698–705
Booij BB, Lindahl T, Wetterberg P et al (2011) A gene expression pattern in blood for the early detection of Alzheimer’s disease. J Alzheimers Dis 23:109–119
Fehlbaum-Beurdeley P, Sol O, Désiré L et al (2012) Validation of AclarusDx™, a blood-based transcriptomic signature for the diagnosis of Alzheimer’s disease. J Alzheimers Dis 32:169–181
Han G, Wang J, Zeng F et al (2013) Characteristic transformation of blood transcriptome in Alzheimer’s disease. J Alzheimers Dis 35:373–386
Wasinger VC, Cordwell SJ, Cerpa-Poljak A et al (1995) Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis 16:1090–1094
Tambor V, Fucíková A, Lenco J et al (2010) Application of proteomics in biomarker discovery: a primer for the clinician. Physiol Res 59:471–497
Thambisetty M, Lovestone S (2010) Blood-based biomarkers of Alzheimer’s disease: challenging but feasible. Biomark Med 4:65–79
Becker M, Schindler J, Nothwang HG (2006) Neuroproteomics – the tasks lying ahead. Electrophoresis 27:2819–2829
Hamacher M, Meyer HE (2005) HUPO Brain Proteome Project: aims and needs in proteomics. Exp Rev Proteomics 2:1–3
Rifai N, Gillette MA, Carr SA et al (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24:971–983
Portelius E, Gustavsson MK, Zetterberg H et al (2012) Evaluation of the performance of novel Aβ isoforms as theragnostic markers in Alzheimer’s disease: from the cell to the patient. Neurodegener Dis 10:138–140
Portelius E, Price E, Brinkmalm G et al (2011) A novel pathway for amyloid precursor protein processing. Neurobiol Aging 32:1090–1098
Perrin RJ, Craig-Schapiro R, Malone JP et al (2011) Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer’s disease. PLoS One 6:e16032
Craig-Schapiro R, Kuhn M, Xiong C et al (2011) Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer’s disease diagnosis and prognosis. PLoS One 6:e18850
Craig-Schapiro R, Perrin RJ, Roe CM et al (2010) YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer’s disease. Biol Psychiatry 68:903–912
Portelius E, Dean RA, Gustavsson MK et al (2010) A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimers Res Ther 2:7
Albertini V, Bruno A, Paterlini A et al (2010) Optimization protocol for amyloid-β peptides detection in human cerebrospinal fluid using SELDI TOF MS. Proteomics Clin Appl 4:352–357
Portelius E, Brinkmalm G, Tran AJ et al (2009) Identification of novel APP/Abeta isoforms in human cerebrospinal fluid. Neurodegener Dis 6:87–94
Simonsen AH, McGuire J, Podust VN et al (2008) Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer’s disease. Neurobiol Aging 29:961–968
Simonsen AH, McGuire J, Hansson O et al (2007) Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol 64:366–370
Simonsen AH, McGuire J, Podust VN et al (2007) A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer’s disease versus normal aging and frontotemporal dementia. Dement Geriatr Cogn Disord 24:434–440
Finehout EJ, Franck Z, Choe LH et al (2007) Cerebrospinal fluid proteomic biomarkers for Alzheimer’s disease. Ann Neurol 61:120–129
Portelius E, Tran AJ, Andreasson U et al (2007) Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res 6:4433–4439
Portelius E, Zetterberg H, Andreasson U et al (2006) An Alzheimer’s disease-specific beta amyloid fragment signature in cerebrospinal fluid. Neurosci Lett 409:215–219
Portelius E, Westman-Brinkmalm A, Zetterberg H et al (2006) Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation–mass spectrometry. J Proteome Res 5:1010–1016
Carrette O, Demalte I, Scherl A et al (2003) A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer’s disease. Proteomics 3:1486–1494
Guo LH, Alexopoulos P, Wagenpfeil S (2013) Plasma proteomics for the identification of Alzheimer disease. Alzheimer Dis Assoc Disord. doi:10.1097/WAD.0b013e31827b60d2
Doecke JD, Laws SM, Faux NG et al (2012) Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 69:1318–1325
Hu WT, Holtzman DM, Fagan AM et al (2012) Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 79:897–905
Soares HD, Potter WZ, Pickering E et al (2012) Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol 69:1310–1317
Johnstone D, Milward EA, Berretta R et al (2012) Multivariate protein signatures of pre-clinical Alzheimer’s disease in the Alzheimer’s disease neuroimaging initiative (ADNI) plasma proteome dataset. PLoS One 7:e34341
O’Bryant SE, Xiao G, Barber R et al (2011) A blood-based algorithm for the detection of Alzheimer’s disease. Dement Geriatr Cogn Disord 32:55–62
O’Bryant SE, Xiao G, Barber R et al (2011) A blood-based screening tool for Alzheimer’s disease that spans serum and plasma: findings from TARC and ADNI. PLoS One 6:e28092
O’Bryant SE, Xiao G, Barber R et al (2010) A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 67:1077–1081
Ray S, Britschgi M, Herbert C et al (2007) Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat Med 13:1359–1362
Hye A, Lynham S, Thambisetty M et al (2006) Proteome-based plasma biomarkers for Alzheimer’s disease. Brain 129:3042–3050
Henriksen K, O’Bryant SE, Hampel H et al (2013) The future of blood-based biomarkers for Alzheimer’s disease. Alzheimers Dement. doi:10.1016/j.jalz.2013.01.013
Gupta VB, Sundaram R, Martins RN (2013) Multiplex biomarkers in blood. Alzheimers Res Ther 5:31
Lista S, Faltraco F, Prvulovic D et al (2013) Blood and plasma-based proteomic biomarker research in Alzheimer’s disease. Prog Neurobiol 101–102:1–17
Blennow K, Hampel H, Weiner M et al (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6:131–144
Portelius E, Zetterberg H, Gobom J et al (2008) Targeted proteomics in Alzheimer’s disease: focus on amyloid-beta. Expert Rev Proteomics 5:225–237
Davidsson P, Sjogren M (2005) The use of proteomics in biomarker discovery in neurodegenerative diseases. Dis Markers 21:81–92
Irizarry MC (2004) Biomarkers of Alzheimer disease in plasma. NeuroRx 1:226–234
Fagan AM, Perrin RJ (2012) Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer’s disease. Biomark Med 6:455–476
Kaddurah-Daouk R, Kristal BS, Weinshilboum RM (2008) Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 48:653–683
Kristal BS, Kaddurah-Daouk R et al (2007) Metabolomics: concept and potential neuroscience application. In: Lajtha A, Gibson G, Dienel G (eds) Handbook of neurochemistry and molecular neurobiology. Brain energetics. Integration of molecular and cellular processes, 3rd edn. Springer, New York, pp 889–912
Sun J, Beger RD, Schnackenberg LK (2013) Metabolomics as a tool for personalizing medicine: 2012 update. Personal Med 10:149–161
Smith CA, Want EJ, O’Maille G et al (2006) XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem 78:779–787
Baker M (2011) Metabolomics: from small molecules to big ideas. Nat Methods 8:117–121
Trushina E, Dutta T, Persson XM et al (2013) Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer’s disease using metabolomics. PLoS One 8:e63644
Han X, MHoltzman D, McKeel DW Jr (2002) Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer’s disease: potential role in disease pathogenesis. J Neurochem 82:809–818
Kaddurah-Daouk R, Krishnan KR (2009) Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 34:173–186
Dunn WB, Broadhurst D, Begley P et al (2011) Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc 6:1060–1083
Cottingham K (2008) HUSERMET researchers look to the metabolome for answers. J Proteome Res 7:4213
Han X (2010) Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer’s disease. Biochim Biophys Acta 1801:774–783
Kaddurah-Daouk R, Zhu H, Sharma S et al (2013) Alterations in metabolic pathways and networks in Alzheimer’s disease. Transl Psychiatry 3:e244
Czech C, Berndt P, Busch K et al (2012) Metabolite profiling of Alzheimer’s disease cerebrospinal fluid. PLoS One 7:e31501
Kaddurah-Daouk R, Rozen S, Matson W et al (2011) Metabolomic changes in autopsy-confirmed Alzheimer’s disease. Alzheimers Dement 7:309–317
Sato Y, Suzuki I, Nakamura T et al (2012) Identification of a new plasma biomarker of Alzheimer’s disease using metabolomics technology. J Lipid Res 53:567–576
Orešič M, Hyötyläinen T, Herukka SK et al (2011) Metabolome in progression to Alzheimer’s disease. Transl Psychiatry 1:e57
Han X, Rozen S, Boyle SH et al (2011) Metabolomics in early Alzheimer’s disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 6:e21643
Wenk MR (2010) Lipidomics: new tools and applications. Cell 143:888–895
Astarita G, Piomelli D (2011) Towards a whole-body systems [multi-organ] lipidomics in Alzheimer’s disease. Prostaglandins Leukot Essent Fatty Acids 85:197–203
Niemelä PS, Ollila S, Hyvönen MT et al (2007) Assessing the nature of lipid raft membranes. PLoS Comput Biol 3:e34
Yetukuri L, Söderlund S, Koivuniemi A et al (2010) Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol. J Lipid Res 51:2341–2351
Kitano H (2002) Systems biology: a brief overview. Science 295:1662–1664
Horvath S, Dong J (2008) Geometric interpretation of gene coexpression network analysis. PLoS Comput Biol 4:e1000117
Langfelder P, Horvath S (2008) WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9:559
Langfelder P, Horvath S (2007) Eigengene networks for studying the relationships between co-expression modules. BMC Syst Biol 1:54
Miller JA, Oldham MC, Geschwind DH (2008) A systems level analysis of transcriptional changes in Alzheimer’s disease and normal aging. J Neurosci 28:1410–1420
Miller JA, Horvath S, Geschwind DH (2010) Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways. Proc Natl Acad Sci U S A 107:12698–12703
Kann MG (2007) Protein interactions and disease: computational approaches to uncover the etiology of diseases. Brief Bioinform 8:333–346
Barabasi AL, Oltvai ZN (2004) Network biology: understanding the cell’s functional organization. Nat Rev Genet 5:101–115
Hallock P, Thomas MA (2012) Integrating the Alzheimer’s disease proteome and transcriptome: a comprehensive network model of a complex disease. OMICS 16:37–49
Prasad TSK, Goel R, Kandasamy K et al (2009) Human Protein Reference Database-2009 update. Nucleic Acids Res 37:D767–D772
Orešič M, Lötjönen J, Soininen H (2010) Systems medicine and the integration of bioinformatic tools for the diagnosis of Alzheimer’s disease. Genome Med 2:83
Acknowledgements
HH and BD would like to thank for the support of the Fondation Pour La Recherche Sur Alzheimer (FRA), Paris, France.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Lista, S., Khachaturian, Z.S., Rujescu, D., Garaci, F., Dubois, B., Hampel, H. (2016). Application of Systems Theory in Longitudinal Studies on the Origin and Progression of Alzheimer’s Disease. In: Castrillo, J., Oliver, S. (eds) Systems Biology of Alzheimer's Disease. Methods in Molecular Biology, vol 1303. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2627-5_2
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2627-5_2
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2626-8
Online ISBN: 978-1-4939-2627-5
eBook Packages: Springer Protocols